Shorted
Pacific Edge logo
PEB

Pacific Edge

Pharmaceuticals, Biotechnology & Life Sciences

Pacific Edge is a global cancer diagnostics company focused on developing and commercializing bladder cancer diagnostic and prognostic tests. Their key product, Cxbladder, is a suite of non-invasive genomic urine tests used for risk stratification, rule-out, and surveillance of urothelial bladder cancer. The company operates directly in New Zealand, Australia, Singapore, and the United States, and through distributors in other regions.

Short position

short percentage0.09%
reported shorts1.1M
shares on issue1.242B

Pacific Edge (ASX:PEB) has 0.09% of its shares on issue reported as short positions as of 5 Oct 2026, or about 1,063,942 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. PEB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

Pacific Edge (PEB) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
25 May

Pacific Edge (ASX:PEB) Medicare Win Sparks Fresh Buzz

Highlights Pacific Edge secured a major US Medicare-related breakthrough tied to cancer diagnostics. The development strengthened discussion around the company’s profitability pathway. Global healthcare diagnostics demand continues lifting attention on precision medicine businesses. Pacific Edge gained renewed attention after a significant Medicare-related breakthrough strengthened discussion around its diagnostics expansion strategy and the growing role of precision medicine in g...

Continue reading
Kalkine
Neutral
15 May

Pacific Edge Expands Funding Base as Healthcare Competition Intensifies

Highlights Pacific Edge expanded its quoted share base through a major placement aimed at strengthening financial flexibility The capital raise reinforced ongoing funding activity across the competitive diagnostics and healthcare technology sector Rising demand for precision diagnostics and personalised healthcare continues reshaping medical testing markets globally Pacific Edge expanded its capital base as diagnostics innovation and healthcare technology transformation continued reshaping me...

Continue reading